### **Accepted Manuscript**

Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma

Yolanda González-Fernández, Hannah K. Brown, Ana Patiño-García, Dominique Heymann, María J. Blanco-Prieto

PII: S0304-3835(18)30363-X

DOI: 10.1016/j.canlet.2018.05.030

Reference: CAN 13914

To appear in: Cancer Letters

Received Date: 27 March 2018
Revised Date: 17 May 2018
Accepted Date: 18 May 2018

Please cite this article as: Y. González-Fernández, H.K. Brown, A. Patiño-García, D. Heymann, M.J. Blanco-Prieto, Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.05.030.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



#### ACCEPTED MANUSCRIPT

# Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma.

Yolanda González-Fernández <sup>a, b, c</sup>, Hannah K. Brown <sup>d</sup>, Ana Patiño-García <sup>b, c</sup>, Dominique Heymann <sup>d,e</sup>\*, María J. Blanco-Prieto <sup>a, c</sup>\*

<sup>a</sup>Department of Pharmacy and Pharmaceutical Technology, University of Navarra, Irunlarrea 1, 31008, Pamplona, Spain

<sup>b</sup>Laboratory of Pediatrics, University Clinic of Navarra, 31008, Pamplona, Spain

<sup>c</sup>Instituto de Investigación Sanitaria de Navarra, IdiSNA, Irunlarrea 3, Pamplona, Spain

<sup>d</sup>INSERM, European Associated Laboratory "Sarcoma Research Unit", Department of Oncology and metabolism, Medical School, University of Sheffield, UK

<sup>e</sup>Institut de Cancérologie de l'Ouest, INSERM, U1232, University of Nantes, 44805 cedex, Saint Herblain, France.

Conflict of interest: Authors have no conflict of interest.

#### \*Corresponding authors

**María J. Blanco-Prieto**. Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, Universidad de Navarra, Irunlarrea 1, 31008 Pamplona, Spain. Email: mjblanco@unav.es; Tel.: +34 948425600; Fax: +34 948425649

**Dominique Heymann**. Institut de Cancérologie de l'Ouest, Inserm, U1232, Blvd Jacques Monod, 44805 Saint-Herblain cedex, France. Email: <a href="mailto:dominique.heymann@univ-nantes.fr">dominique.heymann@univ-nantes.fr</a>; Tel: +33 (0) 240 679 841

#### Download English Version:

## https://daneshyari.com/en/article/8434324

Download Persian Version:

https://daneshyari.com/article/8434324

<u>Daneshyari.com</u>